Case number 1:22-cv-00936
Novo Nordisk Inc. et al v. Biocon Pharma Ltd. et al > Documents
| Date Field | Doc. No. | Description (Pages) |
|---|---|---|
| Nov 8, 2022 | 20 | SCHEDULING & CONSOLIDATION ORDER: THESE ACTIONS ARE CONSOLIDATED FOR ALL PURPOSES AND ALL FUTURE FILINGS SHALL BE MADE IN LEAD CASE NO. 22-CV-897-CFC ONLY. The captions shall be modified to include the words "ANDA CASE" immediately below the Civil Action Number. Joinder of Parties due by 8/11/2023. Amended Pleadings due by 8/11/2023. Fact Discovery completed by 9/8/2023. Expert Discovery due by 1/19/2024. Joint Claim Construction Brief due by 5/23/2023. A Markman Hearing is set for 6/27/2023 at 09:00 AM in Courtroom 4B before Judge Colm F. Connolly. Proposed Pretrial Order due by 3/19/2024. A Final Pretrial Conference is set for 4/9/2024 at 03:00 PM in Courtroom 4B before Judge Colm F. Connolly. A Bench Trial is set for 4/15/2024 at 08:30 AM in Courtroom 4B before Judge Colm F. Connolly. Signed by Judge Colm F. Connolly on 11/8/2022. (nmf) (Entered: 11/08/2022) (30) |
| Nov 1, 2022 | 19 | PROPOSED ORDER -- Scheduling Order -- re (16 in 1:22-cv-00936-CFC, 16 in 1:22-cv-00936-CFC) Order,,, Set Deadlines,, (14 in 1:22-cv-00897-CFC, 14 in 1:22-cv-00897-CFC) Order,,, Set Deadlines,, by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Letter to The Honorable Colm F. Connolly)(Murray, Travis) (Entered: 11/01/2022) (Main Document) (30) |
| Nov 1, 2022 | 19 | PROPOSED ORDER -- Scheduling Order -- re (16 in 1:22-cv-00936-CFC, 16 in 1:22-cv-00936-CFC) Order,,, Set Deadlines,, (14 in 1:22-cv-00897-CFC, 14 in 1:22-cv-00897-CFC) Order,,, Set Deadlines,, by Novo Nordisk A/S, Novo Nordisk Inc.. (Attachments: # 1 Letter to The Honorable Colm F. Connolly)(Murray, Travis) (Entered: 11/01/2022) (Letter to The Honorable Colm F. Connolly) (1) |
| Oct 20, 2022 | 18 | Letter to The Honorable Colm F. Connolly from Brian P. Egan regarding case coordination - re (16 in 1:22-cv-00936-CFC, 16 in 1:22-cv-00936-CFC) Order,,, Set Deadlines,, (14 in 1:22-cv-00897-CFC, 14 in 1:22-cv-00897-CFC) Order,,, Set Deadlines,,. (Egan, Brian) (Entered: 10/20/2022) (2) |
| Oct 14, 2022 | 17 | ANSWER to 13 Answer to Complaint, Counterclaim - by Novo Nordisk A/S, Novo Nordisk Inc..(Murray, Travis) (Entered: 10/14/2022) (13) |
| Sep 30, 2022 | 16 | ORDER, These cases having been recently joined and as these cases are listed as related to earlier filed cases that are currently proceeding on an agreed upon schedule entered by the Court; IT IS ORDERED that, on or before November 1, 2022, counsel for the parties shall confer regarding coordination of the cases and submit a proposed scheduling order to the Court or otherwise advise the Court that a separate scheduling conference is needed. ORDER, Setting Deadlines:(Notice of Compliance deadline set for 11/1/2022.) Signed by Judge Colm F. Connolly on 9/30/2022. Associated Cases: 1:22-cv-00936-CFC, 1:22-cv-00937-CFC(nmf) (Entered: 09/30/2022) (2) |
| Sep 26, 2022 | 15 | MOTION for Pro Hac Vice Appearance of Attorney Rachel J. Schaub and Attorney Christopher W. West - filed by Biocon Ltd., Biocon Pharma Ltd., Biocon Pharma, Inc.. (Dorsney, Kenneth) (Entered: 09/26/2022) (4) |
| Sep 23, 2022 | 13 | ANSWER to 1 Complaint , COUNTERCLAIM against Novo Nordisk A/S, Novo Nordisk Inc. by Biocon Pharma, Inc., Biocon Pharma Ltd., Biocon Ltd..(Hitch, Cortlan) (Entered: 09/23/2022) (24) |
| Sep 23, 2022 | 14 | Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Biocon Pharma Limited for Biocon Pharma, Inc.; Corporate Parent Biocon Limited for Biocon Pharma Ltd. filed by Biocon Ltd., Biocon Pharma Ltd., Biocon Pharma, Inc.. (Hitch, Cortlan) (Entered: 09/23/2022) (2) |
| Sep 19, 2022 | 12 | STIPULATION TO EXTEND TIME for Defendants Biocon Pharma Limited, Biocon Limited and Biocon Pharma, Inc. to answer, move or otherwise respond to the Complaint to September 23, 2022 - filed by Biocon Ltd., Biocon Pharma Ltd., Biocon Pharma, Inc.. (Dorsney, Kenneth) (Entered: 09/19/2022) (2) |
| Aug 22, 2022 | 11 | MOTION for Pro Hac Vice Appearance of Attorney Jeffrey J. Oelke, Ryan P. Johnson, Robert E. Counihan, Laura T. Moran, Erica R. Sutter and Olivia L. Wheeling - filed by Novo Nordisk A/S, Novo Nordisk Inc.. (Egan, Brian) (Entered: 08/22/2022) (12) |
| Aug 3, 2022 | 8 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novo Nordisk Inc., Novo Nordisk A/S: For Biocon Ltd. waiver sent on 7/21/2022, answer due 9/19/2022. (Egan, Brian) |
| Aug 3, 2022 | 9 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novo Nordisk Inc., Novo Nordisk A/S: For Biocon Pharma, Inc. waiver sent on 7/21/2022, answer due 9/19/2022. (Egan, Brian) |
| Aug 3, 2022 | 10 | Waiver of Service Executed (1) Docket Text: WAIVER OF SERVICE returned executed by Novo Nordisk Inc., Novo Nordisk A/S: For Biocon Pharma Ltd. waiver sent on 7/21/2022, answer due 9/19/2022. (Egan, Brian) |
| Jul 22, 2022 | N/A | SO ORDERED (0) Docket Text: SO ORDERED, re [7] MOTION for Pro Hac Vice Appearance of Attorney Matthew M. Holub, Attorney Jitendra "Jitty" Malik, Attorney Deepro R. Mukerjee and Attorney Lance A. Soderstrom, filed by Biocon Pharma, Inc., Biocon Ltd., Biocon Pharma Ltd. Ordered by Judge Colm F. Connolly on 7/22/2022. (kmd) |
| Jul 22, 2022 | N/A | Add Attorneys Pro Hac Vice (0) Docket Text: Pro Hac Vice Attorney Matthew M. Holub, Jitendra M. Malik, Deepro R. Mukerjee, and Lance A. Soderstrom for Biocon Ltd., Biocon Pharma Ltd., and Biocon Pharma, Inc. added for electronic noticing. Pursuant to Local Rule 83.5 (d)., Delaware counsel shall be the registered users of CM/ECF and shall be required to file all papers. (mpb) |
| Jul 22, 2022 | 7 | Motion for Leave to Appear Pro Hac Vice (6) Docket Text: MOTION for Pro Hac Vice Appearance of Attorney Matthew M. Holub, Attorney Jitendra "Jitty" Malik, Attorney Deepro R. Mukerjee and Attorney Lance A. Soderstrom - filed by Biocon Ltd., Biocon Pharma Ltd., Biocon Pharma, Inc.. (Dorsney, Kenneth) |
| Jul 20, 2022 | N/A | Case Assigned/Reassigned (0) Docket Text: Case Assigned to Judge Colm F. Connolly. Please include the initials of the Judge (CFC) after the case number on all documents filed. Associated Cases: 1:22-cv-00936-CFC, 1:22-cv-00937-CFC (rjb) |
| Jul 14, 2022 | 1 | Main Document (9) Docket Text: COMPLAINT filed against Biocon Ltd., Biocon Pharma Ltd., Biocon Pharma, Inc. ( Filing fee $ 402, receipt number ADEDC-3915660.) - filed by Novo Nordisk Inc., Novo Nordisk A/S. (Attachments: # (1) Exhibit A-C, # (2) Civil Cover Sheet)(twk) |
| Jul 14, 2022 | 1 | Exhibit A-C (47) |
| Jul 14, 2022 | 1 | Civil Cover Sheet (2) |
| Jul 14, 2022 | 2 | Magistrate Consent Forms (3) Docket Text: Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (twk) |
| Jul 14, 2022 | 3 | ANDA Form (1) Docket Text: Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: June 11, 2022. Date of Expiration of Patent: U.S. Patent No. 7,762,994 expires on 11/23/2024 with PED; U.S. Patent No. 8,114,833 expires on 2/13/2026 with PED; and U.S. Patent No. 9,265,893 expires on 3/23/2033 with PED. Thirty Month Stay Deadline: 12/11/2024. (twk) |
| Jul 14, 2022 | 4 | Patent/Trademark Report to Commissioner (1) Docket Text: Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,762,994 B2; 8,114,883 B2; 9,265,893 B2. (twk) |
| Jul 14, 2022 | 5 | Disclosure Statement (2) Docket Text: Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent Novo Nordisk US Holdings, Inc. for Novo Nordisk Inc.; Corporate Parent Novo A/S, Other Affiliate Novo Nordisk US Holdings Inc. for Novo Nordisk A/S filed by Novo Nordisk A/S, Novo Nordisk Inc.. (twk) |
| Jul 14, 2022 | 6 | Main Document (2) Docket Text: Summons Issued as to Biocon Ltd., Biocon Pharma Ltd., Biocon Pharma, Inc. on 7/15/2022. (Attachments: # (1) Summons - Biocon Pharma, Inc., # (2) Summons - Biocon Pharma Ltd.)(twk) |
| Jul 14, 2022 | 6 | Summons Issued (2) |
| Jul 14, 2022 | 6 | Summons Issued (2) |
| Jul 14, 2022 | 1 | Complaint* (1) |
